Developability Assessment And Early Formulation Studies

Developing biologics requires a science‑driven strategy that identifies risks early and builds a strong foundation for future formulation and clinical success. This webinar explores how early developability assessments and pre‑formulation studies provide critical insights into a molecule’s biophysical properties, helping teams evaluate stability, aggregation, and manufacturability before costly challenges arise. By defining a formulation corridor early and benchmarking against known reference molecules, developers can better understand how a candidate behaves under stress, how it aligns with its intended product profile, and what attributes may require optimization.

The session also examines common roadblocks such as selecting candidates with unfavorable properties or translating preclinical formulations into concentrated, clinically suitable forms—issues that often lead to delays or late‑stage failures if not addressed proactively. Attendees will learn how comprehensive characterization, in‑use stability assessments, and holistic formulation planning can de‑risk development and accelerate progress toward clinical trials. Overall, the webinar highlights best practices for selecting the most promising candidates and optimizing early biologics development.